December 18, 2015

AbbVie Completes New Licensing Agreement to Address Growing Demand for HIV Treatments in Africa

Share to Facebook Share to Twitter Share to Linkedin Email SUBSCRIPTION MANAGEMENT
Media Statement
AbbVie and the Medicines Patent Pool (MPP) have completed a new licensing agreement to address future demands for HIV-1 treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa.  The agreement has been reached to help ensure sustainable, long-term supply of LPV/r in South Africa and the African continent.  LPV/r is a component of the most widely used HIV-1 treatment for second-line patients in the region. Our company is committed to providing treatment to people living with HIV and believes that Africa’s increased HIV testing efforts requires a strategy which is appropriate for Africa.  AbbVie has a longstanding and ongoing commitment to people living with HIV-1 worldwide. 

Read the announcement from the MPP here.
For further information please contact:
For Africa Media Inquiries:
Ahmed Negm
ahmed.negm@abbvie.com

For Global Media Inquiries:
Ilke Limoncu
ilke.limoncu@abbvie.com